… ARPIs, including abiraterone acetate (Zytiga), … tolerability, comorbidities, drug–drug interactions, and … trials, reinforcing the external validity of trial … prostate cancer has entered an era of routine treatment intensification. Multiple ARPIs, chemotherapy …

… prostate cancer that has spread. The treatment is recommended for people where chemotherapy … eligible for the drug. Clinical trials found that … prostate cancer recommended by NICE in recent months, following darolutamide and abiraterone for prostate cancer …

… prostate cancer will have access to cheaper medicines on the Pharmaceutical Benefits Scheme (PBS). Abiraterone … ,200 patients accessed a comparable treatment through the PBS. Without subsidy …

… backbone of treatment for metastatic prostate cancer. However, … Agents such as abiraterone acetate (Zytiga), enzalutamide … advanced prostate cancer. Early involvement of medical oncology, … ARPIs, chemotherapy, targeted therapies, and clinical trial enrollment. …

… prostate cancer still represents an unmet medical … treatment for metastatic castrate-resistant prostate cancer (mCRPC). Eligible patients were chemotherapy … abiraterone treatment or were indicated for docetaxel treatment … is a pharmaceutical company specializing …

… School of Pharmacy and Pharmaceutical Sciences. “A meaningful … for Medicare beneficiaries with cancer who use Part D-covered drugs. … (17.6%) or prostate cancers (13.3%). Researchers projected … Astellas, Pfizer; 6.2%), abiraterone (5.3%) and ibrutinib …

… treatment for men with untreated hormone-relapsed metastatic prostate cancer … standard treatment with abiraterone plus … trial, which included 805 men with castration-resistant prostate cancer … chemotherapy”.  Helen Knight, NICE's director of medicines …

… 42 million Transform trial, delivered in partnership with Prostate Cancer UK, which … potential to revolutionise prostate cancer screening and reduce unnecessary treatment. “The Secretary … NHS expanded access to abiraterone, a treatment that can significantly …

… Clinical trials have shown clear survival benefits for men with prostate cancer that … delivered. Abiraterone is now available as a lower‑cost generic medicine, … effective and evidence-based treatments, with several new prostate cancer drugs rolled over the …

… prostate cancer will finally be able to get treatment with a life-extending drug … abiraterone when he discovered he would be unable to get the drug … abiraterone to include first-line treatment of hormone-sensitive prostate cancer … calculations. The drug has been …